InvestorsHub Logo
Followers 91
Posts 10888
Boards Moderated 6
Alias Born 06/06/2017

Re: None

Monday, 01/13/2020 8:07:48 AM

Monday, January 13, 2020 8:07:48 AM

Post# of 580
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CFRX News